A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
NCT ID: NCT06085924
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
8252912 participants
OBSERVATIONAL
2023-11-07
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* effects of living with COVID-19 and
* how effective is nirmatrelvir-ritonavir in treating COVID-19.
This is a study of two groups of COVID-19 patients in Taiwan.
In Group 1 the below participants were included in the study:
* Patients of all ages.
* Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021.
* Cases of patients registered in the databases.
In Group 2 the below participants were included in the study:
* Participants who are 12 years or older.
* Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.
Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.
The study will look at:
* the nature of Covid-19 disease.
* as well as the experiences of people receiving the nirmatrelvir-ritonavir.
This study will help to:
* understand what type of patients will need to be admitted to hospitals.
* see severe results due to COVID 19 infection.
* have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
NCT05941793
Study of WPV01 in Healthy Subjects
NCT06205329
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
NCT05599802
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
NCT05656443
Study of Ameliorating Effect of COVID-19 mRNA Vaccine in Individuals Immunized With Inactivated Vaccine
NCT04944381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 - Cases of patients registered in the databases of all ages
Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
Disease description
No intervention
Cohort 2 - Cases of patients registered in the databases of ≥12 years of age
Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
SoC
COVID-19 treatment as per government guidance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SoC
COVID-19 treatment as per government guidance
Disease description
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
* Cases of patients registered in the databases
* ≥12 years of age
* Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
Exclusion Criteria
Cohort 2:
* Patients without COVID-19 diagnosis
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Taiwan
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT06085924
Identifier Type: REGISTRY
Identifier Source: secondary_id
C4671061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.